PTK6 was found to be upregulated in many tumor tissues, including breast cancer (Barker et al., 1997), bladder cancer (Xu et al., 2017), non-small cell lung cancer (Zhao et al., 2013), and ovarian cancer (Schmandt et al., 2006), and is associated with adverse outcomes. Here, PTK6 is linked to urinary bladder carcinoma.